Latest Breaking News On - Mild alzheimer - Page 3 : comparemela.com

Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at International Conference on Alzheimer s and Parkinson s Diseases and Related Neurological Disorders | Region

FRAMINGHAM, Mass. (BUSINESS WIRE) Feb 27, 2024

United statesThe cascadeMaidan powerEarvin liangLarry shenGlenn paulyClinical developmentDevelopment for the treatment of alzheimer diseaseAlzheimer research therapyInternational journal of molecular sciencesInternational conference on alzheimerNational institute onAlzheon incDrug administrationInternational conferenceRelated neurological disorders

Longeveron Reports Year-End 2023 Results and Provides Corporate Update

Longeveron Reports Year-End 2023 Results and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMike moyerExchange commissionAmerican heart associationLongeveron incDevelopment expensesLongeveron or companyCompany to hold conference callExchange commission onScientific sessions of the american heart associationReports year endProvides corporatePriorities focusedHypoplastic left heartStudy enrollment anticipatedSurvival data

Clinical hold lifted for Phase 2 trial of XPro1595 in mild Alzheimer s

Clinical hold lifted for Phase 2 trial of XPro1595 in mild Alzheimer s
alzheimersnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alzheimersnewstoday.com Daily Mail and Mail on Sunday newspapers.

Inmune bioDrug administrationPacific rimMild alzheimer

No Decline in Cognition Scores in Patients with Mild Alzheimer s Disease Who Received Simufilam Continuously For 24 Months

ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam.

United statesPuerto ricoSouth koreaRemi barbierEric schoenSuzanne hendrixCassava sciencesPentara corporationA groupGroup of patientsCassava sciences incNational institutes of healthCog scores were stableMild alzheimerGroup averageSimufilam safe

No Decline in Cognition Scores in Patients with Mild Alzheimer s Disease Who Received

ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24. Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24. Oral Simufilam Safe, Well-Tolerated. AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety

A groupGroup of patientsCog scores were stableMild alzheimerGroup averageSimufilam safeAlzheimer simufilam study patients disease phase clinical label cassava decline globe in inc newswire no region sciences